Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Rhea-AI Summary

Bionano Genomics (Nasdaq: BNGO) announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 at 10:30 a.m. ET. Chairman and Interim CEO Al Luderer, PhD, will present and host 1x1 investor meetings.

A live webcast will be available via online registration, and a replay will be accessible on Bionano’s investor relations website (ir.bionano.com) for at least 90 days following the event.

Market Context

The conference appearance can be assessed alongside the interim CEO’s 4,000-share open-market purcha...

Analysis

The conference appearance can be assessed alongside the interim CEO’s 4,000-share open-market purchase at $1.215 per share. That insider buying adds context, while constrained liquidity and the unused S-3 shelf remain risks to monitor.

Key Figures

Conference date: September 14, 2026 Presentation time: 10:30 a.m. ET Investor meetings: 1x1 meetings +1 more

4 metrics

Conference date September 14, 2026 H.C. Wainwright 28th Annual Global Investment Conference

Presentation time 10:30 a.m. ET September 14, 2026 webcast

Investor meetings 1x1 meetings H.C. Wainwright conference

Replay availability at least 90 days Following the conference through the Bionano website

Historical Context

5 past events · Latest: Aug 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 10	Q2 earnings report	Positive	+2.6%	Revenue growth, guidance, and debt retirement preceded a positive 24-hour move.
Jul 27	Earnings scheduling notice	Neutral	+0.9%	Scheduled conference presentation and webcast preceded a 0.93% positive 24-hour move.
Jun 24	Leadership change	Positive	-1.7%	Chief Scientific Officer appointment preceded a 1.74% negative 24-hour move.
Jun 18	Clinical research update	Positive	-1.7%	Reported study growth and broader adoption preceded a 1.72% negative move.
Jun 11	Clinical research update	Positive	+2.6%	Reported OGM studies and diagnostic concordance preceded a 2.59% positive move.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent BNGO news showed three aligned positive or neutral reactions and two divergences, indicating mixed historical price alignment.

Key Terms

optical genome mapping, isotachophoresis, platform-agnostic

3 terms

optical genome mapping technical

"transform the way the world sees the genome through optical genome mapping (OGM)"

Optical genome mapping is a laboratory technique that produces a high-resolution picture of a person’s long DNA strands to find large structural changes such as missing, extra, or rearranged pieces. For investors, it matters because the method can improve diagnosis, speed development of genetic tests and therapies, and influence regulatory approvals and market demand for companies offering more accurate or faster genomic tools — think of it as a wide-angle camera that reveals large-scale defects traditional microscopes might miss.

isotachophoresis technical

"nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP)"

Isotachophoresis is a laboratory technique that uses an electric field to separate and concentrate charged molecules in a sample by letting each type form its own zone like cars sorting into lanes by speed. It’s used to pull tiny amounts of specific ions or biomolecules out of complex mixtures, making tests more sensitive and faster. For investors, that can mean smaller, cheaper diagnostic devices, quicker lab workflows, and stronger performance for assays or point‑of‑care products.

platform-agnostic technical

"an industry-leading, platform-agnostic genome analysis software solution"

Software, tools, or services that work across different devices, operating systems, or hosting environments without needing special changes or a specific brand. Think of it like a universal remote that controls many TV models: it broadens the potential user base, reduces dependence on one vendor or platform, and can speed adoption and cut integration costs — factors investors watch because they affect market reach, revenue resilience, and scalability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026.

Conference & Webcast Details

Date:	September 14, 2026
Time:	10:30 a.m. ET
Presenter:	Al Luderer, PhD, Chairman and Interim CEO of Bionano
Webcast:	Register Here

A replay / recording of the session will be available following the conference through the Bionano website at ir.bionano.com for at least 90 days.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for clinical, translational, medical, and basic research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit bionano.com or bionanolaboratories.com.

Bionano’s products are for research use only and not for use in diagnostic procedures.

CONTACTS

Company Contact:
Al Luderer, Chairman & Interim CEO
Bionano Genomics, Inc.
+1 (781) 507-4438
Aluderer@bionano.com

Investor Relations:
Webb Campbell
Gilmartin Group
+1 (415) 520-5817
IR@bionano.com

FAQ

When will Bionano Genomics (BNGO) present at the H.C. Wainwright 28th Annual Global Investment Conference in 2026?

Bionano Genomics will present on September 14, 2026, at 10:30 a.m. ET. According to Bionano, Chairman and Interim CEO Al Luderer, PhD, will lead the session and also host one-on-one investor meetings that day.

Who will present for Bionano Genomics (BNGO) at the H.C. Wainwright 2026 conference?

Bionano’s presenter will be Al Luderer, PhD, Chairman and Interim CEO. According to Bionano, he will deliver the company presentation at 10:30 a.m. ET and participate in 1x1 meetings with investors during the conference.

How can investors access the Bionano Genomics (BNGO) webcast from the H.C. Wainwright 2026 conference?

Investors can access the webcast by using the conference’s “Register Here” link provided by Bionano. According to Bionano, a replay will also be available on the company’s investor relations site at ir.bionano.com after the event.

Will a replay of Bionano Genomics’ (BNGO) H.C. Wainwright 2026 presentation be available?

Yes, a replay will be available on Bionano’s investor relations website for at least 90 days. According to Bionano, investors can visit ir.bionano.com after the conference to view the recorded session.

What does Bionano Genomics (BNGO) do in genome analysis and diagnostics?

Bionano provides genome analysis solutions, including optical genome mapping, diagnostic services, and analysis software. According to Bionano, it offers OGM systems for research, platform-agnostic software, ITP-based nucleic acid extraction, and OGM-based diagnostic testing via Bionano Laboratories.

Are Bionano Genomics (BNGO) products intended for diagnostic use in clinical practice?

Bionano states its products are for research use only and not for diagnostic procedures. According to Bionano, while it offers OGM-based diagnostic testing services through Bionano Laboratories, the company specifies that its products are not cleared for routine clinical diagnosis.